BCV has announced that it has secured €6 million in a Series A round of financing led by Forepont Capital Partners, with other investors including NTI, MEDCO and existing French investors. This Series A funding brings the total amount raised since the company’s inception to €13 million.
In a press release, BCV said that its Series A round remains open until 31 March 2024.
“Forepont is proud to lead BCV’s Series A raise to support the advancement of BCV’s superior technology that has already been endorsed by over 100 international interventional radiology experts in the USA and in Europe,” said Frederic Batoua, a partner at Forepont Capital Partners.
“Our technology, applied to a guidewire, will be a disruptive change in minimally invasive procedures improving patients’ outcomes,” added Raphaël Blanc, chairman and co-founder of BCV.
The funding will accelerate the development of BCV’s range of active mechatronic guidewires, from manufacturing to go-to-market. BCV states that it has already built a plant in Reims, France to secure in-house manufacturing, and research and development evolution toward miniaturisation.
“This round of financing will enable BCV to progress toward FDA [Food and Drug Administration] and CE-mark approval,” stated Thierry Col, chief executive officer of BCV. “Forepont and NTI will accelerate BCV’s development, first in the US market thanks to a premier network in endovascular access.”
BCV’s patented innovation consists of an actuable guidewire controlled by a smart handle and a generator. The system’s shape-memory alloy technology enables distal tip control, improving practitioners’ gestures and demonstrating superior performance over existing advanced actuation technologies, BCV claims.
“BCV creates an opportunity to simplify and speed up access in complicated anatomies—a critical part of all endovascular procedures,” said Adnan Siddiqui (The Jacobs Institute, Buffalo, USA).
This steerable mechatronic guidewire is designed to enhance safety, reduce procedure time and produce better outcomes, providing support during critical interventions performed for stroke or artery diseases, BCV’s release concludes.
